Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um weitere News abzurufen!
      OK      
x
Impact News +++ Ad-hoc News: SUSS MicroTec SE (EQS) +++ SUSS MICROTEC Aktie +8,45%

MYRIAD GENETICS Aktie

 >MYRIAD GENETICS Aktienkurs 
12.1 EUR    -5.5%    (Tradegate)
Ask: 12.2 EUR / 407 Stück
Bid: 12.1 EUR / 415 Stück
Tagesumsatz: 910 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>MYRIAD GENETICS Performance
1 Woche: -13,6%
1 Monat: -12,3%
3 Monate: -45,5%
6 Monate: -51,8%
1 Jahr: -36,1%
laufendes Jahr: -4,7%
>MYRIAD GENETICS Aktie
Name:  MYRIAD GENETICS DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US62855J1043 / 897518
Symbol/ Ticker:  MYD (Frankfurt) / MYGN (NASDAQ)
Kürzel:  FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN
Index:  -
Webseite:  https://myriad.com/
Marktkapitalisierung:  1300 Mio. EUR
Umsatz:  803.8 Mio. EUR
EBITDA:  -33.09 Mio. EUR
Gewinn je Aktie:  -1.21 EUR
Schulden:  139.66 Mio. EUR
Liquide Mittel:  97.5 Mio. EUR
Umsatz-/ Gewinnwachstum:  11.2% / -
KGV/ KGV lG:  - / 156.25
KUV/ KBV/ PEG:  1.59 / 1.82 / 1.46
Gewinnm./ Eigenkapitalr.:  -14.09% / -16.4%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  MYRIAD GENETICS
Letzte Datenerhebung:  15.01.25
>Eigentümer
Aktien: 91.04 Mio. St.
f.h. Aktien: 83.48 Mio. St.
Insider Eigner: 2.01%
Instit. Eigner: 102.58%
Leerverk. Aktien: 5.15%
>Peer Group

 
15.01.25 - 15:18
Myriad Genetics Reports Preliminary Q4 Results; Issues 2025 Outlook (AFX)
 
WASHINGTON (dpa-AFX) - Myriad Genetics (MYGN) reported preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Fourth quar......
15.01.25 - 15:18
Myriad Genetics expects Q4 revenues to be between $209M and $211M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.01.25 - 14:34
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance (GlobeNewswire EN)
 
Myriad Genetics announces select preliminary fourth quarter and full year 2024 financial results and introduces full year 2025 financial guidance....
10.01.25 - 14:30
MYGN Stock Gains Following Collaboration With Hannah Storm (Zacks)
 
Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador....
10.01.25 - 02:37
Myriad Genetics Partners With Hannah Storm To Promote Breast Cancer Risk Assessment Program (AFX)
 
WASHINGTON (dpa-AFX) - Myriad Genetics Inc. (MYGN) announced an agreement with Hannah Storm, a nationally renowned sports broadcaster, who recently revealed her battle with breast cancer.As per th......
09.01.25 - 22:33
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History (GlobeNewswire EN)
 
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history....
08.01.25 - 17:30
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference....
08.01.25 - 14:03
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference....
06.01.25 - 14:03
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report (GlobeNewswire EN)
 
Myriad Genetics released its Quality, Innovation, and Corporate Responsibility Report....
20.12.24 - 15:15
MYGN Stock Might Gain From the New Recognition of RiskScore Study (Zacks)
 
The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine....
19.12.24 - 22:18
Myriad Genetics′ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics (GlobeNewswire EN)
 
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine....
17.12.24 - 13:33
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? (Zacks)
 
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar....
11.12.24 - 00:30
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing (GlobeNewswire EN)
 
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing....
10.12.24 - 22:09
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member (GlobeNewswire EN)
 
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members....
10.12.24 - 14:18
New NCCN Guidelines Boost Myriad Genetics′ Prolaris: Stock to Gain? (Zacks)
 
Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment....
10.12.24 - 14:06
Myriad Genetics′ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines (GlobeNewswire EN)
 
Myriad Genetics' full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines....
09.12.24 - 22:09
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium (GlobeNewswire EN)
 
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium....
09.12.24 - 14:03
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics′ Prolaris® Test as an ′Advanced Tool′ Recommended for Prognostic Assessment (GlobeNewswire EN)
 
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer....
25.11.24 - 14:19
MYGN Stock Up on Integration of HRD Platform Into Illumina′s TSO 500 v2 (Zacks)
 
Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay....
20.11.24 - 22:36
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina′s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 (GlobeNewswire EN)
 
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina's updated comprehensive gene panel assay, TruSight™ Oncology 500 v2....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Stolz wie der eines reich gewordenen Armen. - Sprichwort Frankreich
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!